On 3 October 2024, Teva Pharmaceuticals and mAbxience (majority owned by Fresenius Kabi) each announced that they have entered into a new global licensing agreement for the development of an unnamed anti PD-1 oncology biosimilar candidate. Under the agreement, mAbxience will develop the biosimilar, with Teva managing regulatory approvals and commercialisation in multiple markets, including Europe and the US.
The new licensing agreement expands upon an agreement entered into by the two companies in April 2024 in relation to an unnamed oncology biosimilar candidate.